

# A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

NCT07462377

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1
<b>Sponsor</b>	EpiBiologics
<b>Enrollment</b>	110 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Participant has a life expectancy  $\geq$  12 weeks at Day 1.
- Participant has an ECOG performance status of 0-2.
- Participant has pathologically confirmed NSCLC or HNSCC.
- o For NSCLC: the tumor harbors any documented EGFR mutation, insertion, or deletion.
- Participant has locally advanced or metastatic NSCLC or HNSCC.

... and 1 more (see full listing online)

### Exclusion (3)

- Participant has history of uncontrolled illness.
- Participant has symptomatic brain metastases.
- Participant has a diagnosis of any secondary malignancy within 3 years prior to enrollment, except for those patients treated with curative intent and no evidence of active disease.

## Locations (5 total)

---

START Los Angeles, Los Angeles, California, United States  
Astera Cancer Care, East Brunswick, New Jersey, United States  
Sarah Cannon and HCA Research Institute, Nashville, Tennessee, United States  
... and 2 more locations